Comparative Efficacy and Safety of Anti-PD-1/PD-L1 Immune Checkpoint Inhibitors for Refractory or Relapsed Advanced Non-Small-Cell Lung Cancer—A Systematic Review and Network Meta-Analysis

SIMPLE SUMMARY: Improving treatment strategies for refractory or relapsed advanced non-small-cell lung cancer (NSCLC) remains a challenge. Efficacy and safety of the immune checkpoint inhibitors (ICIs), nivolumab (Niv) plus atezolizumab (Atz), were compared with those of ramucirumab (Ram) plus docet...

Descripción completa

Detalles Bibliográficos
Autores principales: Ando, Koichi, Manabe, Ryo, Kishino, Yasunari, Kusumoto, Sojiro, Yamaoka, Toshimitsu, Tanaka, Akihiko, Ohmori, Tohru, Ohnishi, Tsukasa, Sagara, Hironori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7796092/
https://www.ncbi.nlm.nih.gov/pubmed/33561074
http://dx.doi.org/10.3390/cancers13010052

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7796092/
https://www.ncbi.nlm.nih.gov/pubmed/33561074
http://dx.doi.org/10.3390/cancers13010052

Ejemplares similares